Search clinical trials for: Mirdametinib

Total 12 results

Children's Hospital Medical Center, Cincinnati

Recruiting

Mirdametinib in Histiocytic Disorders

Histiocytic Disorders | Juvenile Xanthogranuloma (JXG) | Langerhans Cell Histiocytosis (LCH) | Rosai-Dorfman Disease (RDD)

United States
Centre Georges Francois Leclerc

Not yet recruiting

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK)

Non-Small Cell Lung Cancer
SpringWorks Therapeutics, Inc.

Active, not recruiting

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)

Plexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)

United States
BeiGene
SpringWorks Therapeutics, Inc.

Recruiting

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

Solid Tumor, Adult

Australia, United States
SpringWorks Therapeutics, Inc.

Available

Individual Patient Compassionate Use of Mirdametinib

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas | Histiocytic Neoplasm | Other MAP-K Pathway Driven Diseases
St. Jude Children's Research Hospital
SpringWorks Therapeutics, Inc.

Recruiting

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Low-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade Glioma

United States
SpringWorks Therapeutics, Inc.

Recruiting

Mirdametinib + BGB-3245 in Advanced Solid Tumors

Advanced Solid Tumor

United States, Australia
Johns Hopkins University
Neurofibromatosis Therapeutic Acceleration Program

Recruiting

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). (Mirda)

Cutaneous Neurofibroma | NF1 | Monotherapy

United States
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
Memorial Sloan Kettering Cancer Center

Completed

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Breast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV | Solid Carcinoma | HER2-negative Breast Cancer | MEK1 Gene Mutation | MEK2 Gene Mutation

United States
Koen van Besien

Active, not recruiting

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
Jennifer Eva Selfridge

Suspended

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States

Search clinical trials for: Mirdametinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations